Q120 remained a bright spot showing positive growth with modest disruption from COVID-19 for the quarter.For Q120, according to BioMedGPS’ SmartTRAK Financial Dashboard, the US Infection Prevention - Vascular Access Adjunct Products market was up +4. 4% YoY. The prevention of Hospital-Acquired Infections (HAIs) continues to drive measures and practices to reduce Central Line-Associated Bloodstream Infections (CLABSIs) and is creating demand for products that can address these issues. Numerous programs and educational tools are being developed to provide measures and strategies that assist healthcare providers in the prevention and reduction of infection in acute care and other settings.
Among the many topics covered in the comprehensive Q120 Infection Prevention: Vascular Access Adjunct Products Recap Market Recap* are: